【摘要】 目的评价氯吡格雷联用泮托拉唑是否比氯吡格雷单独使用增加心血管疾患高危患者心血管事件的发生。方法从Medline、High Wire Press、EMBASE、Elsevier Science、Cochrane图书馆和中国期刊全文数据库、万方博硕论文数据库(未限定时间)检索研究氯吡格雷联用质子泵抑制剂是否增加心血管事件发生的临床对照试验文献。采用统计软件Review Manager4.2对各项研究行Meta分析。结果共有4项研究符合入选标准。分析结果表明,氯吡格雷联合泮托拉唑使用相比氯吡格雷单独使用并不明显增加心血管事件的发生(OR=1.04,95%可信区间:0.92～1.18)。结论对于抗血小板治疗而同时需服用质子泵抑制剂的患者,泮托拉唑可作为首选。更多还原

【Abstract】 Objective To perform a meta-analysis of cardiovascular outcomes in patient taking clopidogrel,with and without concomitant pantoprazole.Methods Searched Medline,EMBASE,Cochrone Library,CNKI,Wanfang database for control studies that reported the risk of cardiovascular events with PPI exposure in patients taking clopidogrel.Original data were extracted,pooled odd ratio(OR) and 95% confidence interval(CI) were calculated using Review Manager 4.2.Results The review included 4 studies.Meta-analysis of 4 studies showed no significant association between pantoprazole use and cardiovascular events(OR=1.04,95%CI:0.92～1.18).Conclusion Pantoprazole is the best choice for patients who have to receive clopidogrel plus a PPI.更多还原